David J. Schlanger, the Executive Chairman of Progyny, Inc. (NASDAQ:PGNY), has recently acquired 150,000 shares of the company's common stock, according to a filing with the Securities and Exchange Commission. This insider purchase comes as the stock trades near its 52-week low of $13.39, having declined over 46% in the past six months. According to InvestingPro analysis, the company maintains a "GREAT" financial health score. The shares were purchased on December 26 at a weighted average price of $14.6822 per share, with the transaction valued at approximately $2.2 million. The shares were acquired in multiple transactions, with prices ranging from $14.60 to $14.81. Following this purchase, Schlanger now holds 228,269 shares directly. InvestingPro data reveals the company holds more cash than debt and maintains strong liquidity with a current ratio of 2.62. For deeper insights into insider trading patterns and 12+ additional ProTips, subscribers can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Progyny, a fertility benefits management company, reported a 2% year-over-year revenue increase to $286.6 million in its third-quarter earnings call, along with an expansion in clients and covered lives. Despite facing near-term hurdles, JPMorgan continues to believe in Progyny's long-term fundamentals, which include a 21.7% gross margin and positive net income expectations for the year. However, analyst firms Jefferies and Cantor Fitzgerald have adjusted their price targets for Progyny, citing immediate challenges and an unclear path to overcoming them. Jefferies reduced its price target to $19 while maintaining a buy rating, and Cantor Fitzgerald lowered its target to $22 but held onto an overweight rating. Notably, Progyny maintains a robust cash position of $235 million with no debt and projects sustained profitability into 2025. The company's total addressable market is projected to grow from $10 billion to $50 billion by 2030, with product expansions expected to contribute between 8-10% to annual revenue by 2028. These are recent developments in Progyny's performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.